Tegaserod

CHEMBL76370 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

301.4 g/mol

LogP

2.6

Phase

4

Tegaserod is a selective partial agonist of serotonin 5-HT4 receptors in the gastrointestinal tract that stimulates peristaltic reflexes, intestinal secretion, and reduces visceral sensitivity, originally used for irritable bowel syndrome with constipation and chronic idiopathic constipation. It was withdrawn from the US market due to cardiovascular risks but has been reapproved at lower doses for IBS-C in women under 65 without cardiovascular disease. Research has also explored its potential neuroprotective effects in Alzheimer's disease through serotonergic pathways.

Moleküler Ağırlık

301,3900 g/mol

LogP

2,60

TPSA

87,80 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Infectious Disease Respiratory Disease Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Type 2 Diabetes Cardiovascular Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12

InChI

InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+

Molecular Formula

C16H23N5O

HBD / HBA

3 / 3

Döndürülebilir Bağlar

8

Ağır Atomlar

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Tegaserod is a selective partial agonist of serotonin 5-HT4 receptors in the gastrointestinal tract that stimulates peristaltic reflexes, intestinal secretion, and reduces visceral sensitivity, originally used for irritable bowel syndrome with constipation and chronic idiopathic constipation. It was withdrawn from the US market due to cardiovascular risks but has been reapproved at lower doses for IBS-C in women under 65 without cardiovascular disease. Research has also explored its potential neuroprotective effects in Alzheimer's disease through serotonergic pathways.

Yes, Tegaserod is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL76370. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 135409453. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Tegaserod PillFYI'da

Yapı

Hızlı Veriler

Formül: C16H23N5O
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.